Recruiting
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab - CC-93538-DDI-001
Oppdatert:
15 februar, 2024
|
ClinicalTrials.gov
Fase
Kjønn
Aldersgruppe
Sted(er)
Recruiting
Inclusion Criteria: - Active Eosinophilic esophagitis (EoE) with histologic evidence as a peak count of ≥ 15 eosinophils per higher-power field at any 2 levels of the esophagus - Previously received an adequate trial of proton-pump inhibitor medication that did not provide complete response to EoE - EoE symptoms documented in daily diary during the screening period Exclusion Criteria: - On a regimen of therapeutic anticoagulation - Demonstrates evidence of immunosuppression or is receiving systemic immunosuppressive or immunomodulating drugs - Currently receiving a high potency topical corticosteroid for dermatologic use Other protocol-defined inclusion/exclusion criteria apply
Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon
MLTNO2000046